Higher dose requirements with insulin detemir in type 2 diabetes-Three cases and a review of the literature

Diabetes Research and Clinical Practice

Volumn 84, Issue 2, 2009, Pages

  Swinnen, Sanne G H A ^a   DeVries, J Hans ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Insulin detemir; Insulin therapy; Long acting insulin analogues; Type 2 diabetes

Indexed keywords

INSULIN DETEMIR; INSULIN GLARGINE;

ADULT; ARTICLE; BODY MASS; CASE REPORT; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SUBSTITUTION; FEMALE; HUMAN; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT DURATION;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEIGHT GAIN;

EID: 63649151673     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.02.009     Document Type: Article

References (9)

1. Hermansen K., Davies M., Derezinski T., Martinez Ravn G., Clauson P., Home P., et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29 (2006) 1269-1274
2. Home P., Bartley P., Russell-Jones D., Hanaire-Broutin H., Heeg J.E., Abrams P., et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 27 (2004) 1081-1087
3. Philis-Tsimikas A., Charpentier G., Clauson P., Ravn G.M., Roberts V.L., and Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin. Ther. 28 (2006) 1569-1581
4. Rosenstock J., Davies M., Home P., Larsen J., Koenen C., and Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51 (2008) 408-416
5. Havelund S., Plum A., Ribel U., Jonassen I., Volund A., Markussen J., et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm. Res. 21 (2004) 1498-1504
6. Kurtzhals P., Schaffer L., Sorensen A., Kristensen C., Jonassen I., Schmid C., et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49 (2000) 999-1005
7. Wutte A., Plank J., Bodenlenz M., Magnes C., Regittnig W., Sinner F., et al. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 115 (2007) 461-467
8. Hompesch M., Troupin B., Heise T., Elbroend B., Endahl L., Haahr H., et al. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diabetes Obes. Metab. 8 (2006) 568-573
9. U.S. Food and Drug Administration Center for Drug Evaluation and Research, Levemir Insulin Detemir [rDNA origin] Injection, 2005. Available from http://www.fda.gov/cder/foi/nda/2005/021-536_LevemirTOC.htm.